Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Munder

Showing results (51-60 of 88) with videos related to

Pageof 9
Sort By:
Blood Cancer Journal|April 10, 2019
Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trialKatja C Weisel, Christof Scheid, Manola Zago, et al.
Plos One|May 30, 2013
Cytotoxicity of tumor antigen specific human T cells is unimpaired by arginine depletionMarkus Munder, Melanie Engelhardt, Diana Knies, et al.
Plos Neglected Tropical Diseases|March 11, 2016
Successful Treatment of Human Visceral Leishmaniasis Restores Antigen-Specific IFN-γ, but not IL-10 ProductionEmebet Adem, Fitsumbirhan Tajebe, Mulusew Getahun, et al.
Plos Neglected Tropical Diseases|July 22, 2017
Disease severity in patients with visceral leishmaniasis is not altered by co-infection with intestinal parasitesFitsumbrhan Tajebe, Mulusew Getahun, Emebet Adem, et al.
Oncoimmunology|October 6, 2018
The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myelomaMohamed H S Awwad, Katharina Kriegsmann, Julian Plaumann, et al.
British Journal of Haematology|February 8, 2021
Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trialVania Hungria, Meral Beksac, Katja C Weisel, et al.
Annals of Hematology|June 5, 2025
Ixazomib-lenalidomid-dexamethasone (IRd) in relapsed refractory multiple myeloma (RRMM)-multicenter real-world analysis from Germany and comparative review of the literatureHanna Löffler, Magdalena Braun, Heike Reinhardt, et al.
Frontiers in Immunology|December 15, 2016
Visceral Leishmaniasis Patients Display Altered Composition and Maturity of Neutrophils as well as Impaired Neutrophil Effector FunctionsEndalew Yizengaw, Mulusew Getahun, Fitsumbrhan Tajebe, et al.
The New England Journal of Medicine|August 25, 2016
Daratumumab, Bortezomib, and Dexamethasone for Multiple MyelomaAntonio Palumbo, Asher Chanan-Khan, Katja Weisel, et al.
Frontiers in Immunology|August 25, 2025
Case Report: Late-onset primary hemophagocytic lymphohistiocytosis leading to the diagnosis of Griscelli syndrome type 2 in a young woman with phenotypically inapparent partial albinismJohanna Rausch, Stephanie Herold, Simone Liebhäuser, et al.
Pageof 9

Showing results (51-60 of 88) with videos related to

Sort By:
Pageof 9
Blood Cancer Journal|April 10, 2019
Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trialKatja C Weisel, Christof Scheid, Manola Zago, et al.
Plos One|May 30, 2013
Cytotoxicity of tumor antigen specific human T cells is unimpaired by arginine depletionMarkus Munder, Melanie Engelhardt, Diana Knies, et al.
Plos Neglected Tropical Diseases|March 11, 2016
Successful Treatment of Human Visceral Leishmaniasis Restores Antigen-Specific IFN-γ, but not IL-10 ProductionEmebet Adem, Fitsumbirhan Tajebe, Mulusew Getahun, et al.
Plos Neglected Tropical Diseases|July 22, 2017
Disease severity in patients with visceral leishmaniasis is not altered by co-infection with intestinal parasitesFitsumbrhan Tajebe, Mulusew Getahun, Emebet Adem, et al.
Oncoimmunology|October 6, 2018
The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myelomaMohamed H S Awwad, Katharina Kriegsmann, Julian Plaumann, et al.
British Journal of Haematology|February 8, 2021
Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trialVania Hungria, Meral Beksac, Katja C Weisel, et al.
Annals of Hematology|June 5, 2025
Ixazomib-lenalidomid-dexamethasone (IRd) in relapsed refractory multiple myeloma (RRMM)-multicenter real-world analysis from Germany and comparative review of the literatureHanna Löffler, Magdalena Braun, Heike Reinhardt, et al.
Frontiers in Immunology|December 15, 2016
Visceral Leishmaniasis Patients Display Altered Composition and Maturity of Neutrophils as well as Impaired Neutrophil Effector FunctionsEndalew Yizengaw, Mulusew Getahun, Fitsumbrhan Tajebe, et al.
The New England Journal of Medicine|August 25, 2016
Daratumumab, Bortezomib, and Dexamethasone for Multiple MyelomaAntonio Palumbo, Asher Chanan-Khan, Katja Weisel, et al.
Frontiers in Immunology|August 25, 2025
Case Report: Late-onset primary hemophagocytic lymphohistiocytosis leading to the diagnosis of Griscelli syndrome type 2 in a young woman with phenotypically inapparent partial albinismJohanna Rausch, Stephanie Herold, Simone Liebhäuser, et al.
Pageof 9